DC360 — Powered by Drug Channels

Analysis

The latest Drug Channels commentary — PBMs, 340B, specialty pharmacy, and the contracts that move the money.

Showing 1631–1640 of 2721

Monday, January 5, 2015

  • Oncology Commercialization & Market Access

    8th Oncology Commercialization & Market Access

    February 24-25, 2015 | San Francisco, CA

    www.cbinet.com/oncology

    The oncology marketplace is a competitive environment in which a strong commercialization strategy is essential for product success. As more products enter the pipeline, how do you ensure that market access is attained? This in-depth and dynamic event examines the implications of recent product approvals (such as Sovaldi) on their value demonstration in the oncology marketplace.

    Join your industry colleagues at the 8th Oncology Commercialization & Market Access Strategies conference to maximize market access and meet commercial goals for both new and existing oncology therapies. Visit www.cbinet.com/oncology for more information.

    Drug Channels readers will save $200 off of the standard registration rate when they use discount code HCE967.*

    *Cannot be combined with other offers or used towards a current registration. Cannot be combined with special category rates. Other restrictions may apply.

    Read more

    Posted by Drug Channels Institute, an HMP Global company on Monday, January 5, 2015

    Labels: Sponsored Post

Friday, December 19, 2014

  • A Holiday Greeting Dance from Drug Channels

    Dear Drug Channels reader,

    Wow. It’s hard to believe that another crazy, busy year is already coming to an end.

    Thank you for welcoming me into your inboxes and browsers. I’ve had fun writing about 2014’s unexpected, unusual, and fascinating developments. I’m grateful to our many sponsors and guest writers. (Email Paula if your company wants to publish a guest post.) Special thanks to the brave souls who joined in the often-spirited discussions below the articles.

    2014 was another big growth year for Drug Channels. We now have about 10,000 subscribers, including almost 1,700 @DrugChannels Twitter followers. Our Drug Channels Institute subsidiary is humming along.

    Drug Channels will return in 2015. In the meantime, please enjoy the video greeting below, which gives you a small taste of my awesome dance skillz. (I'm ready for my dance-off with Star Lord.)

    Have a great holiday! All the best to you and your family,
    Adam
    Read more

    Posted by Drug Channels Institute, an HMP Global company on Friday, December 19, 2014

    Labels: Fun Stuff

Thursday, December 18, 2014

  • December 2014 news update: Walgreens, Express Scripts, Diplomat, AmerisourceBergen, and CVS Health

    December at last! It’s time for our final news roundup of 2014. To help you with the next four nights of Hanukkah, here are four stories that go behind the headlines and highlight notable individuals atop some well-known drug channels companies.
    • Greg Wasson, Walgreen—A behind-the-scenes look at his departure
    • Steve Miller, Express Scripts—A humanizing profile of this vocal PBM executive
    • Phil Hagerman, Diplomat Pharmacy—A cool first-person perspective on growth and going public
    • Peyton Howell, AmerisourceBergen—A worthwhile peek at ABC’s global ambitions
    Plus, The Onion reports that CVS is having trouble quitting cigarette sales. It’s your must-read article of the week!
    Read more

    Posted by Drug Channels Institute, an HMP Global company on Thursday, December 18, 2014

    Labels: Wholesalers, International Drug Channels, PBMs, Pharmacy

Wednesday, December 17, 2014

  • Highlights of CVS Health’s Latest Specialty Market Forecasts

    Yesterday, CVS Health held its annual Analyst Day. The accompanying 224-page slide deck provides great insight into the company’s strategy.

    Senior executives told investors how everything is awesome. There is even a section titled “We Made the Right Moves.” (Really.)

    CVS Health also provided a wealth of data about the pharmacy and managed care market. Below, I highlight some specialty market projections that caught my eye.

    CVS has an unfortunate tendency to change its basis of presentation every year, so be sure to read the slide footnotes to figure out what’s really going on.
    Read more

    Posted by Drug Channels Institute, an HMP Global company on Wednesday, December 17, 2014

    Labels: Specialty Drugs, Biosimilars, Industry Trends, Pharmacy

Tuesday, December 16, 2014

  • What’s Behind Medicare and Medicaid Drug Spending Growth?

    Let’s dip back into the just-released 2013 National Health Expenditure data, which the Centers for Medicare & Medicaid Services (CMS) recently released. In last week's Hospitals and Physicians Spending Outpace Drugs in Latest U.S. Healthcare Spending Data, I compare drug spending growth with spending growth of other healthcare services.

    Today, I delve into drug spending trends by payer. As I describe below, policy and population changes led to significant drug spending growth by Medicare and Medicaid, while private health insurance and consumers paid less.

    The 2013 numbers provide a peek at the forces that will change drug payment in the coming years. Don't say you weren't warned!
    Read more

    Posted by Drug Channels Institute, an HMP Global company on Tuesday, December 16, 2014

    Labels: Health Care Policy, Costs/Reimbursement, Medicare Part D

Monday, December 15, 2014

  • Government Drug Pricing Forum

    Government Drug Pricing Forum
    February 11-13, 2015
    Embassy Suites Washington DC Convention Center, Washington. DC

    With the increase in complexity of government pricing and contracting, the Conference Forum is no longer holding its Medicaid Rebate Summit. Instead, it is expanding its coverage and presenting the Government Drug Pricing Forum (GDP). The GDP Forum will cover changes in MDRP, 340B, Tricare and Medicaid Managed Care. It specifically addresses the AMP Final Rule, AMP-based FULs, proposed HRSA guidance, rise of contract pharmacies, and new state reporting requirements impact government and commercial contracting rules and operations. This event brings together CMS, FDA, IRS, HRSA, States and OIG to address how to be compliant with separate agency requirements.

    Register today! Drug Channels readers receive a 15% discount with code DC15.

    Featured Speakers include:

    • Lori Reilly, PhRMA
    • Laurel Todd, BIO
    • Don Bell, National Association Chain Drug Store (NACDS)
    • Ann Maxwell, Office of Evaluation and Inspections, Office of Inspector General
    • Andrew Wilson, McKesson
    • Alice Valder Curran, Hogan Lovells
    • John Shakow, King & Spaulding
    • Kathleen Black, Pfizer
    • George Kenny, Genentech
    • Stephanie Kupski, Iroko Pharmaceuticals
    • Ed McAdam, Daiichi Sankyo
    • Jay McKinley, Dendreon
    • Lorraine Moccio, Johnson & Johnson
    Conference Topics
    • Healthcare Trends and Policy Expectations: From ACOs and AMP to Contract Pharmacies
    • New State Reporting Requirements and Tricare Contracting
    • Drug Channel Contracting Strategies
    • Compliant Government Pricing Programs
    February 11th Workshop Choices
    Register today! Drug Channels readers receive a 15% discount with code DC15.

    Read more

    Posted by Drug Channels Institute, an HMP Global company on Monday, December 15, 2014

    Labels: Sponsored Post

Thursday, December 11, 2014

Tuesday, December 9, 2014

  • Hospitals and Physicians Outpace Drugs in New U.S. Healthcare Spending Data

    Last week, the econowonks at the Centers for Medicare & Medicaid Services (CMS) released the 2013 National Health Expenditure data. Savor the numbers in this Health Affairs article: National Health Spending In 2013: Growth Slows, Remains In Step With The Overall Economy. (Free download)

    It’s fashionable to blame healthcare spending growth on pharmaceuticals, but it’s also inaccurate. In 2013, prescription drug spending grew by 2.5%, which was 110 basis points behind the 3.6% growth in overall expenditures.

    Our analysis also shows that spending on hospital care and physician services, which account for a majority of healthcare expenditures, grew more quickly than drug spending. See the chart below.

    CMS projects that these trends will reverse in 2014, because of healthcare reform’s rollout and Sovaldi’s legendary launch. Until then, don’t blame drugs.
    Read more

    Posted by Drug Channels Institute, an HMP Global company on Tuesday, December 9, 2014

    Labels: Hospitals, Health Care Policy, Industry Trends, Costs/Reimbursement, Physicians, Pharmacy

Monday, December 8, 2014

  • Hub Models and Program Design

    4th Hub Models and Program Design
    February 5-6, 2015 | Philadelphia, PA
    www.cbinet.com/hubs

    With mounting cost pressures and increased demands for affordable, value-based treatment options, bio/pharmaceutical teams face an increasingly competitive specialty market. They also confront a number of challenges in effectively managing product and patient services.

    The 4th Hub Models and Program Design conference brings together key specialty bio/pharmaceutical thought leaders for a dynamic and collaborative, two-day event to help you and your team effectively manage your brand and ensure patient services. Visit www.cbinet.com/hubs for more information.

    Speakers include representatives from: Children’s PKU Network | Cubist Pharmaceuticals | CVS Health | The Dedham Group | Eisai Inc. | Endo Pharmaceuticals | Genzyme | Horizon Health Services | Hyperion Therapeutics | Ipsen Biopharmaceuticals, Inc. | Lash Group, an AmerisourceBergen company | Loeb & Loeb LLP | ProMetrics | Raptor Pharmaceuticals | Relypsa Inc. | Sonexus Health | UBC | Viewpoint Health

    Register today!

    Drug Channels readers will save $200 off the standard registration rate when they use code RGX588.*

    *Cannot be combined with other offers or used towards a current registration. Cannot be combined with special category rates. Other restrictions may apply.

    Read more

    Posted by Drug Channels Institute, an HMP Global company on Monday, December 8, 2014

    Labels: Sponsored Post

Thursday, December 4, 2014

  • McKesson Officially Dominates Celesio

    On Tuesday, McKesson announced that it had achieved operational control over Celesio, the global retail and wholesale company operating in 13 European countries and Brazil. Read the press release.

    Technically, the Stuttgart Higher Regional Court approved the " domination and profit and loss transfer agreement" between Celesio AG and McKesson’s German subsidiary. Domination! Hard to beat that evocative Teutonic M&A terminology.

    The three largest, U.S.-based wholesalers are now all expanding significantly outside North America—a key trend in our 2014-15 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors. The McKesson-Celesio deal exemplifies this new era of global drug distributors. Read on for details.
    Read more

    Posted by Drug Channels Institute, an HMP Global company on Thursday, December 4, 2014

    Labels: Wholesalers, International Drug Channels, Mergers and Acquisitions

Trusted worldwide

Stay Informed. Stay Ahead.

Subscribe to our newsletter for the latest analysis and industry updates.